Cough monitor Resapp (ASX:RAP) has done a deal with telehealth company Phenix Health, following a similar deal by Respiri (ASX:RSH) in April.

The software licensing agreement for its ResAppDX-EU cough diagnostic test was first announced in March with a price of $5-10 per test. CEO Tony Keating is expecting first commercial revenues in the coming months through the agreements with Phenix Health and Coviu.

For the full article please visit: https://stockhead.com.au/experts/scopos-health-powerplays-clinical-trials-are-back/